Toz Hasan, Kavala Ali Aycan, Türkyılmaz Saygın, Kuserli Yusuf, Türkyılmaz Gülsüm, Yesiltas Mehmet Ali, Kılıçaslan Necdet
Department of Cardiovascular Surgery, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey.
Department of Cardiovascular Surgery, ISTUN Sisli Kolan International Hospital, Istanbul, Turkey.
Braz J Cardiovasc Surg. 2025 May 30;40(3):e20240071. doi: 10.21470/1678-9741-2024-0071.
Cardioplegia solution, also called the del Nido solution, has been widely used in pediatric cardiac surgeries, and has recently started to be used in adult cardiac surgeries. In this context, this study aimed to investigate the relationship between the use of del Nido and blood cardioplegia solutions and postoperative atrial fibrillation rates in our clinic.
The study sample comprised 140 patients who underwent coronary artery bypass grafting. The del Nido and blood cardioplegia solutions were used in 70 (50%) patients. The postoperative atrial fibrillation rates of both groups were compared. Additionally, patients' preoperative, intraoperative, and postoperative data were evaluated.
The cardiopulmonary bypass duration and defibrillation rate were lower in the del Nido cardioplegia group than in the blood cardioplegia group (P < 0.001). Atrial fibrillation rates on postoperative days one, five, and 30 were significantly lower in the del Nido cardioplegia group than in the blood cardioplegia group (P < 0.001, P < 0.001, and P = 0.007, respectively).
The postoperative atrial fibrillation rate was significantly lower in the del Nido cardioplegia group than in the blood cardioplegia group. In addition, the del Nido cardioplegia solution did not interrupt the surgical flow, thus resulting in less total perfusion, shorter cross-clamping durations, and fewer defibrillation needs. In conclusion, the del Nido cardioplegia solution can be used safely and effectively in coronary artery bypass grafting surgeries.
心脏停搏液,也称为德尔尼多溶液,已广泛应用于小儿心脏手术,最近也开始用于成人心脏手术。在此背景下,本研究旨在探讨在我们的诊所中使用德尔尼多溶液和血液心脏停搏液与术后房颤发生率之间的关系。
研究样本包括140例行冠状动脉旁路移植术的患者。70例(50%)患者使用了德尔尼多溶液和血液心脏停搏液。比较两组的术后房颤发生率。此外,还评估了患者的术前、术中和术后数据。
德尔尼多心脏停搏液组的体外循环时间和除颤率低于血液心脏停搏液组(P < 0.001)。德尔尼多心脏停搏液组术后第1天、第5天和第30天的房颤发生率显著低于血液心脏停搏液组(分别为P < 0.001、P < 0.001和P = 0.007)。
德尔尼多心脏停搏液组的术后房颤发生率显著低于血液心脏停搏液组。此外,德尔尼多心脏停搏液未中断手术流程,因此总灌注量更少、主动脉阻断时间更短且除颤需求更少。总之,德尔尼多心脏停搏液可安全有效地用于冠状动脉旁路移植手术。